215 related articles for article (PubMed ID: 28741382)
21. Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
Samukawa Y; Sata M; Furihata K; Ito T; Ueda N; Ochiai H; Sakai S; Kumagai Y
Clin Pharmacol Drug Dev; 2017 Sep; 6(5):439-447. PubMed ID: 28783873
[TBL] [Abstract][Full Text] [Related]
22. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better.
Kimura T; Obata A; Shimoda M; Okauchi S; Kanda-Kimura Y; Nogami Y; Moriuchi S; Hirukawa H; Kohara K; Nakanishi S; Mune T; Kaku K; Kaneto H
Diabetes Obes Metab; 2018 Oct; 20(10):2442-2457. PubMed ID: 29873444
[TBL] [Abstract][Full Text] [Related]
23. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
24. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
Shibuya T; Fushimi N; Kawai M; Yoshida Y; Hachiya H; Ito S; Kawai H; Ohashi N; Mori A
Diabetes Obes Metab; 2018 Feb; 20(2):438-442. PubMed ID: 28719078
[TBL] [Abstract][Full Text] [Related]
25. Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Sasaki T; Sugawara M; Fukuda M
J Diabetes Investig; 2019 Jan; 10(1):108-117. PubMed ID: 29660782
[TBL] [Abstract][Full Text] [Related]
26. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
Kojima N; Williams JM; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):464-72. PubMed ID: 23492941
[TBL] [Abstract][Full Text] [Related]
27. Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes.
Kusunoki M; Natsume Y; Sato D; Tsutsui H; Miyata T; Tsutsumi K; Suga T; Oshida Y
Drug Res (Stuttg); 2016 Nov; 66(11):603-606. PubMed ID: 27626603
[TBL] [Abstract][Full Text] [Related]
28. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacological and clinical profile of a new SGLT2 inhibitor, luseogliflozin (Lusefi®)].
Takahashi T; Yamamoto K
Nihon Yakurigaku Zasshi; 2015 Sep; 146(3):150-8. PubMed ID: 26354015
[No Abstract] [Full Text] [Related]
30. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN
Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
[TBL] [Abstract][Full Text] [Related]
31. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.
Sasaki T; Seino Y; Fukatsu A; Sakai S; Samukawa Y
Adv Ther; 2014 Mar; 31(3):345-61. PubMed ID: 24535625
[TBL] [Abstract][Full Text] [Related]
32. Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.
Chino Y; Kuwabara M; Hisatome I
J Clin Pharmacol; 2022 Mar; 62(3):366-375. PubMed ID: 34545949
[TBL] [Abstract][Full Text] [Related]
33. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
[TBL] [Abstract][Full Text] [Related]
34. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
Ejiri K; Miyoshi T; Kihara H; Hata Y; Nagano T; Takaishi A; Toda H; Nanba S; Nakamura Y; Akagi S; Sakuragi S; Minagawa T; Kawai Y; Nishii N; Fuke S; Yoshikawa M; Nakamura K; Ito H;
J Am Heart Assoc; 2020 Aug; 9(16):e015103. PubMed ID: 32805185
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
Samukawa Y; Haneda M; Seino Y; Sasaki T; Fukatsu A; Kubo Y; Sato Y; Sakai S
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):820-828. PubMed ID: 29693800
[TBL] [Abstract][Full Text] [Related]
36. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
37. Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
Bando S; Ichikawa R; Taguchi T; Fujimoto K; Motomiya T; Taguchi M; Takano K; Shichiri M; Miyatsuka T
Endocr J; 2022 Jun; 69(6):681-687. PubMed ID: 35067495
[TBL] [Abstract][Full Text] [Related]
38. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
[TBL] [Abstract][Full Text] [Related]
39. Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.
Kumagai Y; Hasunuma T; Sakai S; Ochiai H; Samukawa Y
PLoS One; 2015; 10(10):e0139873. PubMed ID: 26444986
[TBL] [Abstract][Full Text] [Related]
40. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
Brunton SA
Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
